Biosimilar Contract Manufacturing Market Overview
The Biosimilar Contract Manufacturing Market focuses on the outsourcing of biosimilar drug development and manufacturing activities to specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). Biosimilars are biological medicines that are highly similar to already approved reference biologics, offering potentially more affordable treatment options. Contract manufacturing enables pharmaceutical and biotechnology companies to access advanced production facilities, specialized expertise, scalable manufacturing capabilities, and regulatory support without making extensive investments in their own infrastructure. The global market was valued at approximately USD 7.73 billion in 2024 and is projected to reach USD 51.9 billion by 2035, expanding at a CAGR of 18.9% during 2025–2035.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/11903
Market Drivers
Rising Demand for Cost-Effective Biologic Therapies:
The increasing cost of biologic medicines is encouraging healthcare providers, pharmaceutical companies, and payers to seek more affordable therapeutic alternatives. Biosimilars can provide cost savings compared with reference biologics, increasing their adoption and creating greater demand for specialized contract manufacturing services.
Increasing Prevalence of Chronic Diseases:
The growing incidence of cancer, autoimmune disorders, rheumatoid arthritis, blood disorders, and other chronic diseases is increasing demand for biologic therapies. As biosimilars become more widely adopted for these conditions, pharmaceutical companies are increasingly relying on contract manufacturers with specialized biologics production capabilities.
Patent Expirations of Major Biologic Drugs:
The expiration of patents and exclusivity periods for major biologic medicines is creating opportunities for biosimilar manufacturers. As more reference biologics become available for biosimilar competition, companies are turning to experienced CMOs and CDMOs to accelerate development and commercial-scale production.
Advancements in Biomanufacturing Technologies:
Innovations in cell culture, single-use manufacturing systems, automation, process optimization, and analytical technologies are improving the efficiency and scalability of biosimilar manufacturing. These advancements allow contract manufacturers to produce complex biologics while maintaining quality and regulatory compliance.
Growing Regulatory Support for Biosimilars:
Regulatory agencies across major markets have established pathways for biosimilar development and approval. Increasing regulatory familiarity with biosimilars is encouraging pharmaceutical companies to enter the market and outsource manufacturing to experienced service providers.
Increasing Strategic Partnerships and Outsourcing:
Pharmaceutical and biotechnology companies are increasingly forming partnerships with contract manufacturers to reduce capital expenditure, access specialized expertise, and shorten development timelines. This trend is strengthening the role of CMOs and CDMOs throughout the biosimilar value chain.
Market Challenges
High Manufacturing Complexity:
Biosimilar manufacturing requires sophisticated biological production processes, highly controlled environments, specialized equipment, and extensive analytical testing. Maintaining consistency between batches can be challenging because biologics are inherently more complex than conventional small-molecule drugs.
High Initial Investment:
Establishing biologics manufacturing facilities requires substantial investments in infrastructure, production equipment, quality-control systems, and regulatory compliance. These capital requirements can limit the ability of smaller contract manufacturers to expand their capabilities.
Stringent Regulatory Requirements:
Biosimilar manufacturers must demonstrate a high degree of similarity to the reference biologic in terms of quality, safety, and efficacy. Differences in regulatory requirements across countries can increase development complexity and lengthen approval timelines.
Supply Chain and Manufacturing Risks:
Biosimilar production depends on specialized raw materials, cell lines, culture media, equipment, and highly skilled personnel. Disruptions in global supply chains can affect production schedules and increase manufacturing costs.
Intense Competition Among Contract Manufacturers:
The growing attractiveness of the biosimilar market has encouraged established pharmaceutical companies, CMOs, and CDMOs to expand their manufacturing capabilities. Increasing competition can place pressure on pricing, capacity utilization, and long-term contracts.
Browse In-depth Market Research Report on Biosimilar Contract Manufacturing Market:
https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903
Market Segmentation
By Product Type:
Recombinant Glycosylated Proteins:
Recombinant glycosylated proteins represent a major segment of the biosimilar contract manufacturing market. These complex proteins are widely used in therapeutic areas such as oncology and autoimmune diseases and require advanced mammalian cell-based manufacturing platforms.
Recombinant Non-glycosylated Proteins:
This segment includes biologic products such as insulin, interferons, granulocyte colony-stimulating factors, and human growth hormone. Improvements in recombinant protein production technologies are supporting their continued adoption in biosimilar manufacturing.
By Production Technology:
Mammalian:
Mammalian production technology represents the leading production platform because it enables the manufacture of complex therapeutic proteins with appropriate post-translational modifications. Mammalian cell culture is particularly important for producing sophisticated biosimilars that require structures closely resembling their reference biologics.
Non-Mammalian:
Non-mammalian systems, including bacterial and yeast-based platforms, provide alternative approaches for producing certain recombinant proteins. These technologies can offer advantages related to production speed, scalability, and cost for appropriate biosimilar products.
By Application:
Oncology:
Oncology represents a major application area for biosimilar contract manufacturing due to the growing global burden of cancer and the increasing use of biologic therapies in cancer treatment. The availability of biosimilars can help expand access to biologic oncology medicines.
Blood Disorders:
Biosimilars used in the treatment of blood disorders are contributing to market growth. Increasing demand for affordable biologic treatments and advances in recombinant protein manufacturing are supporting this segment.
Growth Hormonal Deficiency:
The use of recombinant biologics for growth hormonal deficiency creates opportunities for biosimilar development and contract manufacturing, particularly as healthcare systems seek cost-effective treatment options.
Chronic & Autoimmune Disorders:
The increasing prevalence of autoimmune and chronic inflammatory diseases is driving demand for biologic therapies and their biosimilar alternatives. Contract manufacturers support pharmaceutical companies in scaling production to meet this demand.
Rheumatoid Arthritis:
Rheumatoid arthritis is an important application area because biologic medicines are widely used for patients with moderate-to-severe disease. The introduction of biosimilars can improve affordability and increase treatment accessibility.
Others:
Other applications include additional therapeutic areas where biologic medicines are being developed and commercialized as biosimilar alternatives.
By End-User:
Pharmaceutical Companies:
Pharmaceutical companies are major users of contract manufacturing services because outsourcing enables them to access specialized biologics manufacturing capabilities while reducing the need for extensive internal infrastructure.
Biotechnology Companies:
Biotechnology companies frequently partner with CMOs and CDMOs to scale biosimilar candidates from development and clinical production through commercial manufacturing.
Research and Development Organizations:
Research-focused organizations and development partners may use specialized manufacturing services for laboratory, preclinical, and clinical-stage biosimilar programs.
Regional Insights
North America:
North America represents the leading regional market, accounting for more than 45% of global revenue in 2024. The region benefits from advanced healthcare infrastructure, significant biosimilar adoption, strong biologics manufacturing capabilities, and supportive regulatory developments. The United States is the dominant contributor to regional demand.
Europe:
Europe represents another major market for biosimilar contract manufacturing. The region benefits from an established biosimilar regulatory framework, strong pharmaceutical manufacturing infrastructure, and increasing demand for cost-effective biologic medicines. Germany, the UK, and France are among the important markets in the region.
Asia-Pacific:
Asia-Pacific is emerging as a significant growth market due to increasing healthcare expenditure, a large patient population, growing biosimilar adoption, and expanding pharmaceutical manufacturing capabilities. China and India are important contributors, while Japan also represents a developed biosimilar market.
Latin America, Middle East & Africa:
Emerging markets across Latin America, the Middle East, and Africa offer opportunities as healthcare infrastructure improves and governments seek to increase access to affordable biologic medicines. Growing awareness of biosimilars and investments in local pharmaceutical manufacturing are expected to support future market expansion.
Key Players
Samsung Biologics
Lonza Group
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
Catalent
WuXi Biologics
Roche
Amgen
Sandoz
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
Avid Bioservices
Almac Group
These companies compete through manufacturing capacity expansion, advanced bioprocessing technologies, strategic partnerships, quality systems, and global production networks.
Future Outlook
The Biosimilar Contract Manufacturing Market is expected to experience significant growth over the coming years, driven by the increasing demand for affordable biologic therapies, rising prevalence of chronic diseases, patent expirations of major biologic drugs, and continued advancements in biomanufacturing technologies. The market is projected to grow from approximately USD 9.19 billion in 2025 to USD 51.9 billion by 2035, representing a CAGR of 18.9%.
The increasing adoption of outsourcing models is expected to create additional opportunities for CMOs and CDMOs with advanced mammalian cell-culture platforms, scalable manufacturing capacity, sophisticated analytical capabilities, and strong regulatory expertise. Strategic partnerships between pharmaceutical companies and contract manufacturers are also expected to become increasingly important as companies seek to reduce development costs and accelerate biosimilar commercialization.
Future opportunities are likely to include expansion into emerging markets, investment in advanced bioprocessing technologies, development of flexible manufacturing facilities, increased automation and digitalization, and strategic collaborations for biosimilar development and commercial production. As healthcare systems continue to prioritize cost-effective access to biologic therapies, contract manufacturing is expected to remain an important component of the global biosimilar ecosystem.
Related Report:
